IMMX — Immix Biopharma, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1873835 ·
Last close
$7.04
Market Cap
$590.04M
52W High
$15.10
52W Low
$3.78
ADV30
1,186,717
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -15,945,871 | -13,927,180 | 345,948,808 | 320,315,143 | 10,893,546 |
| Jun 2026 | 0 | — | -12,456,343 | -11,557,002 | 239,108,896 | 225,491,985 | 10,192,343 |
| Mar 2026 | 0 | — | -10,803,855 | -10,086,687 | 95,816,057 | 79,250,163 | 11,452,001 |
| Dec 2025 | 0 | — | -10,893,276 | -10,687,830 | 104,840,341 | 93,928,566 | 11,044,171 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-38,498,081
Investing CF
$-9,149,614
Financing CF
$261,522,180
CapEx
$-591,111
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.82
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-126,106,973
Inventory
—
Receivables
$0
ST Investments
$6,615,168
EBIT TTM
$-41,815,983
Pretax Income TTM
$-39,883,901
Interest Exp TTM
—
Analysts
8
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -29,956,415 | -29,438,613 | 104,840,341 | 11,044,171 | 93,796,170 | -23,930,304 |
| Dec 2024 | 0 | -22,674,680 | -21,613,376 | 22,947,872 | 9,696,669 | 13,251,203 | -14,595,102 |
| Dec 2023 | 0 | -16,141,113 | -15,426,048 | 19,925,160 | 3,721,783 | 16,405,114 | -11,371,438 |
| Dec 2022 | 0 | -8,218,948 | -8,229,713 | 14,908,101 | 1,748,296 | 13,159,805 | -7,408,303 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$1,932,082
NetIncome TTM
$-39,917,211
OpCashFlow TTM
—
Assets (Latest)
$239,108,896
Forward EPS
$-0.94
Max Pain — expiry 2027-02-19 (volume-derived — Yahoo OI feed degraded)
max pain strike: $5.00 · spot: $7.04 · call volume: 93 · put volume: 1
Expected Move to 2027-02-19:
±$3.40
(48.30%) —
implied range
$3.64 –
$10.44
· ATM straddle on $7.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| GERN | GERON CORP | $588.19M | $0.91 | — |
| DSGN | Design Therapeutics, Inc. | $596.82M | $9.32 | — |
| AVBP | ArriVent BioPharma, Inc. | $582.40M | $11.26 | — |
| BCAX | Bicara Therapeutics Inc. | $605.45M | $9.12 | — |
| ALMS | ALUMIS INC. | $562.12M | $4.33 | — |
News headlines (Yahoo Finance, 1h cache)
Immix Biopharma Reports Third Quarter 2026 Financial Results and Update on Corporate Progress
2026-11-12 21:15 · Yahoo
Immix Biopharma’s NXC-201 NEXICART-2 Interim Clinical Trial Results Selected for Oral Presentation at ASH 2026
2026-11-04 14:15 · Yahoo
Immix Biopharma (IMMX) Stock Sees Modest Fair Value Lift After Split Analyst Revisions
2026-10-21 04:29 · Yahoo
Immix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare Conference
2026-10-05 12:45 · Yahoo
Immix Biopharma Reports 89% Complete Response in NXC-201 AL Amyloidosis Study
2026-10-05 03:02 · Yahoo
Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock
2026-09-30 21:15 · Yahoo
BofA Raises Odds Of Success For Immix Biopharma’s NXC-201 Therapy — Sees Over 190% Upside In IMMX Stock
2026-09-29 17:48 · Yahoo
Immix Biopharma Reports 89% Complete Response Rate in Phase 2 NXC-201 Trial
2026-09-29 13:34 · Yahoo
Immix Biopharma Announces 89% Complete Response Rate at Interim Update Across All NEXICART-2 Patients, with MRD-Negativity Indicating Potential to Reach up to 98% Complete Response Rate, Supporting Po
2026-09-29 11:00 · Yahoo
Straight Out Of A Soap Opera: Biotech Exec Arrested After 21 Years On The Run
2026-07-21 21:17 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.